Mer­ck scores pri­or­i­ty re­view Keytru­da in squa­mous NSCLC; Syn­thet­ic Ge­nomics spin­out SGI-DNA gets new CEO

→ The FDA has ac­cept­ed — and giv­en pri­or­i­ty re­view — to Mer­ck’s sup­ple­men­tal bi­o­log­ics li­cense ap­pli­ca­tion for its can­cer im­munother­a­py Keytru­da. The phar­ma gi­ant is hop­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER